Chemistry:Linerixibat

From HandWiki

Linerixibat, sold under the brand name Lynavoy, is a medication used for the treatment of cholestatic pruritus. Linerixibat is an ileal bile acid transporter (IBAT) inhibitor.[1]

Linerixibat was approved for medical use in the United States in March 2026.[2][3][4]

Medical uses

Linerixibat is indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis. [2]

References

  1. ↑ "Ileal Bile Acid Transporter Inhibitors for Adult Patients with Autoimmune Cholestatic Liver Diseases: A Systematic Review and Meta-Analysis.". Gastroenterology Insights 16 (3): 30. August 2025. doi:10.3390/gastroent16030030. 
  2. ↑ 2.0 2.1 "Novel Drug Approvals for 2026". 26 March 2026. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026.  Public Domain This article incorporates text from this source, which is in the public domain.
  3. ↑ "Lynavoy (linerixibat) FDA Approval History". 20 March 2026. https://www.drugs.com/history/lynavoy.html. 
  4. ↑ "Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)". GSK (Press release). 19 March 2026. Retrieved 5 April 2026.




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Linerixibat&oldid=4434091"